Asthma UK Centre for Applied Research


Research outputs from members of the Centre, and other relevant publications



Title Authors Summary Reference

Short-acting β2-agonists and exacerbations in children with asthma in England: SABINA Junior.

Morgan A, Maslova E, Kallis C, Sinha I, Roberts G, Tran TN, van der Valk RJP, Quint JK.

Higher SABA prescriptions in children were associated with increased future exacerbation rates,which requires prescription monitoring  of three or more SABA canisters per year.

ERJ Open Res. 2023 Apr 24;9(2):00571-2022. doi: 10.1183/23120541.00571-2022. eCollection 2023 Mar.PMID: 37101737 

Dupilumab Improves Long-term Outcomes in Patients With Uncontrolled, Moderate-to-Severe GINA-Based Type 2 Asthma, Irrespective of Allergic Status.

Rabe KF, Pavord ID, Busse WW, Chupp GL, Izuhara K, Altincatal A, Gall R, Pandit-Abid N, Deniz Y, Rowe PJ, Jacob-Nara JA, Radwan A "Long-term treatment with dupilumab reduced exacerbation rates, and improved lung function and asthma control in patients with asthma with type 2 inflammation".

Allergy. 2023 Apr 19. doi: 10.1111/all.15747. Online ahead of print.PMID: 37073882

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.

Busse WW, Pavord ID, Siddiqui S, Khan AH, Praestgaard A, Nash S, Jacob-Nara JA, Rowe PJ, Deniz Y.J Dupilumab, which is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and -13, (key and central drivers of type 2 inflammation), can significantly improve both CRSwNP and asthma outcomes.  Asthma Allergy. 2023 Apr 18;16:411-419. doi: 10.2147/JAA.S391896. eCollection 2023.PMID: 37096015 

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study.


Pavord I, Gardiner F, Heaney LG, Domingo C, Price RG, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. "In daily clinical practice, mepolizumab treatment enables a subset of patients with severe eosinophilic asthma to achieve the proposed composite definitions of clinical remission, with more than one-third meeting the three-component definition." Front Immunol. 2023 Apr 12;14:1150162. doi: 10.3389/fimmu.2023.1150162. eCollection 2023.PMID: 37122713 

Patient-centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA-EAACI approach.

Bousquet J, Shamji MH, Anto JM, Schünemann HJ, "Although  some   biomarkers exist in specialist care for asthma, they cannot be  largely  used  in  primary  care, and there  are no  validated  biomarkers  in  rhinitis   or  allergen  immunotherapy  (AIT) that can be used in clinical  practice". Allergy. 2023 Apr 11. doi: 10.1111/all.15740. Online ahead of print.PMID: 37042071 

Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD.

Tomaszewski EL, Atkinson MJ, Janson C, Karlsson N, Make B, Price D, Reddel HK, Vogelmeier CF, Müllerová H, Jones PW. CAAT demonstrated good cross-sectional psychometric properties and moderate-strong correlations with other health status measures, making it a suitable PRO instrument to assess the impact of obstructive lung disease in broad populations of patients with airways disease. It might be relevant for routine clinical practice and ‘real-world’ effectiveness studies performed in patients in a routine care setting. NOVELTY Scientific Community; and the NOVELTY study investigators.Respir Res. 2023 Apr 8;24(1):106. doi: 10.1186/s12931-023-02394-6.PMID: 37031164

Identifying and appraising outcome measures for severe asthma: a systematic review.

Rattu A, Khaleva E, Brightling C, Dahlén SE, Bossios A, Fleming L, Chung KF, Melén E, Djukanovic R, Chaudhuri R, Exley A, Koppelman GH, Bourdin A, Rusconi F, Porsbjerg C, Coleman C, Williams C, Nielsen H, Davin E, Taverner P, Romagosa Vilarnau S, Roberts G. "This review identified 96 ‘candidate’ outcome measures and used a multi-stakeholder consensus process to select 24 ‘priority’ outcome measures for adult and paediatric severe asthma." 3TR Consortium Respiratory Work Package.Eur Respir J. 2023 Apr 3;61(4):2201231. doi: 10.1183/13993003.01231-2022. Print 2023 Apr.PMID: 36549712 

Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).

Khaleva E, Rattu A, Brightling C, Bush A, Bossios A, Bourdin A, Chung KF, Chaudhuri R, Coleman C, Dahlén SE, Djukanovic R, Deschildre A, Fleming L, Fowler SJ, Gupta A, Hamelmann E, Hashimoto S, Hedlin G, Koppelman GH, Melén E, Murray CS, Pilette C, Porsbjerg C, Pike KC, Rusconi F, Williams C, Ahrens B, Alter P, Anckers F, van den Berge M, Blumchen K, Brusselle G, Clarke GW, Cunoosamy D, Dahlén B, Dixey P, Exley A, Frey U, Gaillard EA, Giovannini-Chami L, Grigg J, Hartenstein D, Heaney LG, Karadag B, Kaul S, Kull I, Licari A, Maitland-van der Zee AH, Mahler V, Schoos AM, Nagakumar P, Negus J, Nielsen H, Paton J, Pijnenburg M, Ramiconi V, Romagosa Vilarnau S, Principe S, Rutjes N, Saglani S, Seddon P, Singer F, Staudinger H, Turner S, Vijverberg S, Winders T, Yasinska V, Roberts G "This patient-centred collaboration has produced two COM sets for paediatric and adult severe asthma. It is expected that they will inform the methodology of future clinical trials, enhance comparability of efficacy and effectiveness of biological therapies, and help assess their socioeconomic value. COMSA will inform definitions of non-response and response to biological therapy for severe asthma." ; COMSA Working Group in the 3TR Consortium.Eur Respir J. 2023 Apr 3;61(4):2200606. doi: 10.1183/13993003.00606-2022. Print 2023 Apr.PMID: 36229046

Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study.

Sousa-Pinto B, Jácome C, Pereira AM, Regateiro FS, Almeida R, Czarlewski W, Kulus M, Shamji MH, Boulet LP, Bonini M, Brussino L, Canonica GW, Cruz AA, Gemicioglu B, Haahtela T, Kupczyk M, Kvedariene V, Larenas-Linnemann D, Louis R, Niedoszytko M, Pham-Thi N, Puggioni F, Romantowski J, Sastre J, Scichilone N, Taborda-Barata L, Ventura MT, Vieira RJ, Agache I, Bedbrook A, Bergmann KC, Amaral R, Azevedo LF, Bosnic-Anticevich S, Brusselle G, Buhl R, Cecchi L, Charpin D, Loureiro CC, de Blay F, Del Giacco S, Devillier P, Jassem E, Joos G, Jutel M, Klimek L, Kuna P, Laune D, Luna Pech J, Makela M, Morais-Almeida M, Nadif R, Neffen HE, Ohta K, Papadopoulos NG, Papi A, Pétré B, Pfaar O, Yeverino DR, Cordeiro CR, Roche N, Sá-Sousa A, Samolinski B, Sheikh A, Ulrik CS, Usmani OS, Valiulis A, Vandenplas O, Vieira-Marques P, Yorgancioglu A, Zuberbier T, Anto JM, Fonseca JA, Bousquet J. "e-DASTHMA is a good tool for the daily assessment of asthma control. This tool can be used as an endpoint in clinical trials as well as in clinical practice to assess fluctuations in asthma control and guide treatment optimisation."

Lancet Digit Health. 2023 Apr;5(4):e227-e238. doi: 10.1016/S2589-7500(23)00020-1. Epub 2023 Mar 3.PMID: 36872189 

Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.

Pavord ID, Deniz Y, Corren J, Casale TB, FitzGerald JM, Izuhara K, Daizadeh N, Ortiz B, Johnson RR, Harel S, Djandji M, Goga L, Crikelair N, Rowe PJ, Busse WW. "Increased baseline FeNO was associated with greater clinical effects in dupilumab versus placebo independently of eosinophil levels and other clinical characteristics." J Allergy Clin Immunol Pract. 2023 Apr;11(4):1213-1220.e2. doi: 10.1016/j.jaip.2022.11.043. Epub 2022 Dec 16.PMID: 36535524 





Publications 2020-2018

A summary of selected relevant publications by members of the Asthma UK Centre for Applied Research is available as both a PDF and an EXCEL sheet. Includes publications up to and including October 2020.